Tau PET in Imaging and Cognition: Healthy Adults From 55-90
| Status: | Recruiting |
|---|---|
| Conditions: | Alzheimer Disease, Cognitive Studies, Cognitive Studies, Healthy Studies |
| Therapuetic Areas: | Neurology, Psychiatry / Psychology, Other |
| Healthy: | No |
| Age Range: | 55 - 90 |
| Updated: | 1/10/2019 |
| Start Date: | June 1, 2018 |
| End Date: | December 2023 |
| Contact: | Ashley Mensing, BS |
| Email: | anm2186@cumc.columbia.edu |
| Phone: | 212-305-6314 |
Tau Positron Emission Tomography (PET) in Imaging and Cognition
The investigators aim to use the new PET radioligand, 18F-MK-6240, to detect tau pathology in
cognitive healthy and mild cognitive impairment (MCI) elders. The investigators will then
examine the interactions between differential tau burden and performance on cognitive tasks,
functional magnetic resonance imaging (fMRI) neural activation patterns, and other cognitive
and behavioral measures. By investigating these relationships, the investigators hope to
understand the cognitive and behavioral outcomes of tau deposition found in specific brain
regions in cognitively normal/mildly cognitively impaired adults. Furthermore, the study aims
to examine how the presence of tau may contribute to the risk of subsequent cognitive
decline, neurodegeneration, and dementia.
cognitive healthy and mild cognitive impairment (MCI) elders. The investigators will then
examine the interactions between differential tau burden and performance on cognitive tasks,
functional magnetic resonance imaging (fMRI) neural activation patterns, and other cognitive
and behavioral measures. By investigating these relationships, the investigators hope to
understand the cognitive and behavioral outcomes of tau deposition found in specific brain
regions in cognitively normal/mildly cognitively impaired adults. Furthermore, the study aims
to examine how the presence of tau may contribute to the risk of subsequent cognitive
decline, neurodegeneration, and dementia.
Many cognitively healthy older adults have, upon post mortem evaluations, been found to have
varying amounts of neurofibrillary tangles (tau) and beta-amyloid plaque deposits, which are
the hallmark brain pathologies known to be associated with Alzheimer's disease and various
other dementias. While some with these pathologies may not clinically express cognitive
decline or dementia in their lifetime, human post-mortem studies suggest that increasing
neurofibrillary tangle density correlates with neurodegeneration and cognitive impairment.
Imaging tauopathy in-vivo provides an opportunity to examine neurocognitive correlates of
differential levels of tauopathy in the brain, allowing to further qualify pre-clinical
states of cognitive impairment. The investigators aim to investigate possible protective
mechanisms, such as cognitive reserve, that may modulate the relationship between tauopathy
and cognitive decline.
varying amounts of neurofibrillary tangles (tau) and beta-amyloid plaque deposits, which are
the hallmark brain pathologies known to be associated with Alzheimer's disease and various
other dementias. While some with these pathologies may not clinically express cognitive
decline or dementia in their lifetime, human post-mortem studies suggest that increasing
neurofibrillary tangle density correlates with neurodegeneration and cognitive impairment.
Imaging tauopathy in-vivo provides an opportunity to examine neurocognitive correlates of
differential levels of tauopathy in the brain, allowing to further qualify pre-clinical
states of cognitive impairment. The investigators aim to investigate possible protective
mechanisms, such as cognitive reserve, that may modulate the relationship between tauopathy
and cognitive decline.
Inclusion Criteria:
- Aged 55-90
- Previously participated in protocol # AAAQ8096: Amyloid PET
- Residing near Columbia University Medical Center
- Must be willing and able to participate
Exclusion Criteria:
- Have a contraindication to PET (e.g, metallic implants, pacemaker, claustrophobia, or
cannot lie flat for one hour)
- Pregnancy
- Lactating Women
- Current, past, or anticipated exposure to radiation
- Significant active physical illness
We found this trial at
1
site
630 W 168th St
New York, New York
New York, New York
212-305-2862
Principal Investigator: Yaakov Stern, PhD
Phone: 212-305-6314
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
Click here to add this to my saved trials
